Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter eye treatment put to the test against standard crosslinking

NCT ID NCT03922542

Disease control Sponsor: Price Vision Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers compare two versions of corneal crosslinking to treat progressive keratoconus or corneal ectasia, conditions where the cornea thins and bulges. Both use riboflavin eye drops and ultraviolet light, but one delivers the light faster and more intensely. The trial measures changes in corneal shape and vision to see whether the quicker method works as well as the standard one.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
riboflavin eye drops activated by ultraviolet light
What this could lead to
If the accelerated version works as well as the standard one, patients could spend far less time in the treatment chair while still strengthening the cornea.
What could go wrong
The accelerated treatment may not harden the cornea as effectively as the standard version, and crosslinking carries risks of infection, haze, or slow healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

508 people

The number who actually took part.

Started

Apr 2019

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented keratoconus or ectasia after refractive surgery Exclusion Criteria: * Insufficient corneal thickness * Ocular condition that may predispose the eye to complications * History of chemical injury or delayed epithelial healing * Condition that would interfere with or prolong epithelial healing * Known sensitivity to treatment medications * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ectasia corneal are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corneal ectasia keratoconus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ectasia corneal Keratoconus

Contacts and locations

Locations

  • Price Vision Group

    Indianapolis, Indiana, 46260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.